theMednet - For a patient with stage 4 lung cancer PDL1 TPS > 50% and long term history of myasthenia gravis stable on mycophenolate, would you ever consider pembrolizumab or would this be absolute contraindication?

Topics: Thoracic Malignancies • Medical Oncology

For a patient with stage 4 lung cancer PDL1 TPS > 50% and long term history of myasthenia gravis stable on mycophenolate, would you ever consider pembrolizumab or would this be absolute contraindication?

Answer from: Medical Oncologist at Community Practice

Myasthenia gravis is one of the autoimmune conditions that I would consider a contraindication for immunotherapy. If myasthenia flares, the consequences are life-threatening, and can become extremely difficult to treat. I have personally experienced a patient who developed de novo myasthenia on immu...

Related Questions